Background. Many patients with chronic obstructive lung disease show increased airways responsiveness to histamine. We investigated the hypothesis that increased airways responsiveness predicts the development and remission of chronic respiratory symptoms. Methods. We used data from 24-year follow-up (1965-90) 
The "Dutch hypothesis" was originally put forward by
The core point at the beginning of the 1960s was Orie et al. 1 They postulated that airway hyperthat the Dutch hypothesis pointed to endogenous factors responsiveness (AHR) and atopy were markers of a which might play an important role in the development basic disturbance or constitution which predisposed to of COPD. This contrasted with the view that exogenous the development of chronic non-specific lung disease factors-particularly tobacco smoke-were the overcharacterised by cough, sputum production, dyspnoea, whelming causes of COPD. and often airflow limitation. This disease, later termed CARA in Dutch, included both chronic asthma and what we would today label as chronic obstructive pulmonary disease (COPD). Retrospectively, it seems that Atopy, airways hyperresponsiveness, and the risk this lack of distinction between asthma and COPD-at a of COPD time when most British, other European, and American
The role of atopy has gradually been separated from studies made a clear distinction-was a major hindrance that of AHR, at least in epidemiological studies. In for communication between the Dutch group and several studies total IgE has been used as a marker of others. Also, the "Dutch hypothesis" was not a term atopy. In general, smokers have an increase in total IgE proposed by Orie et al but by others contrasting it and also in blood eosinophil count compared with nonwith the "British hypothesis" which focused on chronic smokers. In the absence of clinical asthma there is, mucus hypersecretion as a marker of recurrent airway infections causing chronic airflow limitation.
however, no indication that atopy interacts with tobacco smoking, and atopy is not believed to be a true risk more likely than subjects without to develop a variety of respiratory symptoms (chronic cough, chronic sputum factor for COPD. 2 3 The other endogenous component of relevance is expectoration, dyspnoea, asthmatic attacks, persistent wheeze) in any following three year period (odds ratios believed to be AHR. This has been the focus of increasing research within the last few years since various of 1.4-3.7 adjusted for age, sex, smoking status, and area of residence). Odds ratios tended to be larger for refinements of the diagnostic provocation procedures have enabled measurement of AHR in large studies, asthma-like symptoms, persistent wheeze, and asthma attacks than for "bronchitis" which was defined as both in population studies to evaluate epidemiology 3 and in the area of randomised clinical trials. [4] [5] [6] Due to episodes of cough and phlegm lasting for at least three weeks in the past three years. Furthermore, patients minor and somewhat dubious differences, 7 8 histamine seems to have been favoured over methacholine in with increased airways responsiveness were less likely to report remission of symptoms than those without studies on COPD.
AHR is clearly related to the presence of pulmonary increased responsiveness. The strength of the study lies in its sample size, its two symptoms 9 10 and level of lung function. [10] [11] [12] [13] This has been known for years but often provokes no more distinct cohorts, and the appropriate use of advanced statistical methods. It does, however, have one limthan a "chicken and egg" discussion as histamine or methacholine tests in chronic airflow obstruction initation. The results were said to be uninfluenced by the exclusion of "asthmatics" but no definition of the latter variably suggest AHR for geometric reasons alone. The association between forced expiratory volume in one was provided. Presumably the authors relied on selfreported physician made diagnoses. The relationship second (FEV 1 ) and apparent AHR deserves careful attention 14 15 and there is a need for a consensus on between AHR and the clinical symptoms of asthma is well founded and so the inclusion of asthmatic subjects the most appropriate way of taking airway calibre into account before there is any attempt to quantify the level is likely to have introduced some bias. We would have expected, conversely, some weakening of the demof airway responsiveness. A detailed discussion of this methodological issue is, however, beyond the scope of onstrated associations after exclusion of asthmatic subjects. The authors have nevertheless collected and this review.
AHR has also been shown to be an independent risk analysed invaluable data which strengthen the overall credibility of AHR as an important aetiological factor factor for an accelerated decline in FEV 1 in a number of large cohort studies including a study originating in chronic respiratory disease. from the Groningen group, 16 a study by Villar et al in the elderly, 17 and the Normative Aging study.
Furthermore, an association between AHR at baseline Airways hyperresponsiveness and other risk factors for COPD and five year decline in FEV 1 was present in the Lung Health Study. 6 The apparent impact of AHR on the Thus, AHR seems to be an independent risk factor for the development of COPD, presumably acting as a decline in FEV 1 has varied between studies, but on average the presence of AHR appears to add ap-"constitutional factor" as suggested by the Dutch hypothesis. This poses the further interesting question of proximately 10 ml/year to the decline in FEV 1 . The effect is largest in populations of elderly subjects. 17 A how the AHR risk links with other established risk factors. review of the epidemiological literature on AHR and the decline in FEV 1 has been made by Rijcken and It is worth noting that the clinical diagnosis of COPD is ususally "cross-sectional"-that is, the diagnosis is Weiss, 20 co-authors of the introductory article. The above studies all looked at lung function data made after demonstrating irreversible airflow limitation after the apparent exclusion of a few (and rare) specific measured on two or more occasions, the first with concurrent measures of AHR and FEV 1 . With subconditions that can also cause fixed airway obstruction. It is not generally diagnosed after the longitudinal obsequent FEV 1 measurements the initial AHR from such studies can be related to the change in FEV 1 . If it servation of an excessive decline in FEV 1 . The distinction from asthma is most often achieved from the explains a significant part of the FEV 1 variation, the hypothesis that AHR is a risk factor for an excess FEV 1 clinical history, a history of smoking and other exposures such as dust and fumes, serial measurements of spirodecline is supported. Although analysing this decline in FEV 1 is not without pitfalls, 21 an association between metric values or peak flow, measurements of parenchymal lung function, or (when doubt remains) AHR and subsequent FEV 1 decline now seems established. It should be noted, however, that AHR-like corticosteroid reversibility or the quantification of airway responsiveness. This clinical approach does not always all other biological phenomena-varies over time. A given threshold may lead subjects to be labelled "hyperdistinguish between the several ways in which the affected individual may have acquired a low level of lung reactive" at some times and "normal" at others. For this reason there is a need for studies which are able to function. 20 The different possibilities are shown in fig 1 where the normal course of growth and decline in FEV 1 look at changes in AHR and changes in FEV 1 as well as other disease outcomes in order to demonstrate is shown. One of the main obstacles for the acceptance of the consistency.
Dutch hypothesis has always been the "downgrading" of the role of tobacco smoking. In the literature on COPD the attributable risk of tobacco smoking is genThe introductory article The introductory article by Xu and colleagues stems erally believed to be 80-90%. At the same time only 15% of smokers develop COPD, a phenomenon generally from an almost ideal cohort study which has measured AHR every third year for a 24 year period in the ascribed to the presence or absence of various degrees of "susceptibility". rural Vlagtwedde and urban Vlaardingen populations of Holland. Increased airways responsiveness to histamine
The growth phase for the lungs (or at least lung function) has recently been shown to be affected by was defined as a provocative concentration causing a fall in FEV 1 of 10% or more (PC 10 ) of <8 mg/ml. smoking, especially in girls, 23 and from early cross sectional studies it seems that AHR is associated with a Subjects with increased airways responsiveness were group.bmj.com on June 26, 2017 -Published by http://thorax.bmj.com/ Downloaded from While statistical interactions are often treated with little attention, we find this lack of interaction disturbing and we believe it represents a major obstacle to accepting AHR as the underlying marker of susceptibility. Without a demonstrable interaction between AHR and a strong environmental factor such as tobacco smoke, AHR should be seen as no more than a further independent risk factor for COPD along with smoking, rather than as a more fundamental mechanism by which smoking exerts its influence. Another way of demonstrating that AHR and smoking interact in causing airway obstruction would be by determining whether attenuation of AHR can slow down the progression of airflow obstruction 
22
focusing on this point are clearly needed.
Chronic mucus hypersecretion has re-emerged as a risk factor for an accelerated FEV 1 decline 31 32 and recent studies have suggested a more obvious impact of smoklower maximally attained level of FEV 1 . The growth pattern is largely unknown, but the association is readily ing on lung function in symptomatic than in asymptomatic subjects. 25 32 No studies have looked at interactions observed in growing children with persistent asthma. 24 No studies have looked at interactions between AHR between mucus hypersecretion and AHR, and both may represent markers of an inflammatory component in the and smoking although the growth of lung function seems to be more markedly reduced in symptomatic smokers disease. 33 34 than in asymptomatic smokers. 25 It is generally believed that in healthy non-smokers a plateau phase of lung function occurs in early adulthood,
The heterogeneity of COPD and the Dutch hypothesis generally spanning the ages 25-35 years, 25 but this belief may be partly the result of combining measurements of Another impediment to widespread acceptance of the Dutch hypothesis has been the reluctance to accept a continued slow growth in some subjects with those of slow decline in others. 26 Smoking shortens the plateau common background for diseases with such differing pathophysiology as asthma and emphysema. Instead of phase whereas little is known about the influence of AHR.
rejecting the hypothesis on these grounds it may be worthwhile taking a broader view. Recent work has suggested that, contrary to previous "common knowledge", female gender seems to be a From clinical and pathological studies it is clear that COPD may arise as a consequence of emphysema with further risk factor for COPD. 27 28 From the viewpoint of the Dutch hypothesis a higher prevalence of AHR in destruction of lung tissue and loss of elastic recoil, a dramatic example of this being the terminal phase of women provides the means for greater susceptibility to the harmful effects of smoking. Such an increased 1 -antitrypsin deficiency. On the other hand, end stage COPD may be seen with virtually no emphysema, the prevalence was reported from the Lung Health Study 29 but this was initially ascribed to geometric differences severe airflow limitation being a consequence of small airways dysfunction. This is due to thickening of the in airways calibre. However, subsequent analyses have shown that the difference cannot be explained solely by airway wall and fibrotic changes following remodelling processes-an obstructive bronchiolitis. With growing geometric factors. In a recent French paper Leynaert et al 30 found that young women were more hyperreactive recognition of this heterogeneity of COPD (quite apart from COPD+asthma) it is clear that no one hypothesis than men. With AHR defined as a provocative dose of methacholine causing a 20% fall in FEV 1 (PD 20 ) of will be able to fully explain its pathogenesis; it may be fruitful to consider the many pathways to or causes of Ζ4 mg/ml, 37.3% of women were hyperreactive and 18.6% of men. The difference could not be attributed COPD, or the spectrum of COPD, rather than COPD alone. While it may be appropriate for initial diagnosis to differences in height. The study also suggested that a larger proportion of the AHR found in women was and management to regard COPD as a single entity and proceed according to guidelines recently pubassociated with smoking. This implies that this greater susceptibility to smoking might be mediated by AHR, lished, 35 the search for underlying mechanisms needs to follow other leads. In this respect the Dutch hypothesis though the introductory article does not support such a hypothesis.
can make a valuable contribution. The close connection between AHR and asthma and It is tempting to regard AHR as the marker of susceptibility for COPD, and the study of Leynaert et al its apparent additional relation to COPD requires comment in any update on the Dutch hypothesis. In a supports this. However, larger studies have not been able to demonstrate an interaction between AHR and further paper to the introductory article, Rijcken et al 36 argued that distinguishing between asthma and COPD smoking in analyses of the decline in FEV 1 . If AHR in smokers is important in the pathogenesis of progressive in epidemiology is of little use. This may be so, particularly for studies looking strictly at FEV 1 decline or airflow obstruction, epidemiological studies should be able to demonstrate a statistical interaction between mortality. For the clinician, however, the clinical picture is often distinguishable and it makes sense to separate AHR and smoking-a statistical "interaction" being roughly equivalent to clinical "susceptibility". So far no asthma from COPD in terms of treatment strategies, treatment goals, etc. Nevertheless, the traditional view publication has been able to report this, the introductory article being no exception.
that lung function in asthma typically remains normal group.bmj.com on June 26, 2017 -Published by http://thorax.bmj.com/ Downloaded from LEARNING POINTS * Airway hyperresponsiveness (AHR) is associated with respiratory symptoms, level of lung function, and decline in lung function. * Changes in AHR are associated with changes in respiratory symptoms, seemingly in both asthmatic and non-asthmatic subjects. * AHR is a risk factor for COPD, independent of age and tobacco consumption. * The reported relationship of AHR with gender needs further evaluation. * Future studies of respiratory epidemiology may benefit from looking at changes in the risk factor of interest as well as at changes in the outcome variable-for example, the methodology reported in the introductory article. Fletcher and coworkers of London transport workers. We conclude that the "Dutch hypothesis" is still with 
